Partner Headlines - BMRN

  1. The FDA Just Crushed Sarepta Therapeutics' Hopes Of Releasing ...

    Benzinga
  2. Sarepta Plummets As FDA Slams Muscular Dystrophy Drug

    IBD
  3. BioMarin Muscular Dystrophy Drug Rejected By FDA

    IBD
  4. BioMarin Announces Interim Analysis of INSPIRE Clinical Trial ...

    Benzinga
  5. BioMarin, Intercept hit by FDA

    IBD
  6. BioMarin, Intercept Pharma Drugs Face FDA Delays

    IBD
  7. BioMarin Announces That FDA Has Advised it Will Not Take Action ...

    Benzinga
  8. Pharmaceutical Stocks Hold Prominent Positions in Kyle Bass' ...

    GuruFocus
  9. FDA Panel Seen As Bad For BioMarin, Good For Sarepta

    IBD
  10. FDA Advisory Committee Discusses Clinical Data Package for BioMarin's ...

    Benzinga
  11. BioMarin Drug's Future In Doubt After FDA Panel Vote

    IBD
  12. BIOMARIN PHARMA

    IBD
  13. KaloBios, Valeant Lead Week's 5 Top Drug Stock Gainers

    IBD
  14. Here's Why Sarepta Is Skyrocketing While BioMarin Is Falling

    Benzinga
  15. Morning Market Losers

    Benzinga
  16. Benzinga's Top #PreMarket Losers

    Benzinga
  17. Goldman Sachs' Top 4 Smid-Cap Biotech Picks

    IBD
  18. Benzinga's Top Initiations

    Benzinga
  19. Biotech ETFs: Buy, Buy, Buy?

    Benzinga
  20. Hurricane Hillary Shifts Left, Slamming More Stocks

    IBD
  21. PTC Stock Seesaws On Muscular Dystrophy Drug Data

    IBD
  22. BioMarin's Initial 6-Month Data From Phase 2 Study of Vosoritide ...

    Benzinga
  23. Sarepta Stock Soars On New Muscular-Dystrophy Data

    IBD
  24. BioMarin to Acquire Rights to Phenylketonuria (PKU) Franchise ...

    Benzinga
  25. Wednesday's After-Hours Movers: PBF Energy, BioMarin Pharmaceutical ...

    Benzinga
  26. Stocks Rally, Will Gains Hold? Biotechs Try Second Rebound

    IBD
  27. Benzinga's Top #PreMarket Losers

    Benzinga
  28. Amgen And Biogen Lead Short Interest Surge In Biotechs

    Benzinga
  29. BioMarin Announces Two Oral and 19 Poster Presentations at the ...

    Benzinga
  30. Medivation to Expand Global Oncology Franchise With the Acquisition ...

    GuruFocus
  31. Benzinga's M&A Chatter for Monday August 24, 2015

    Benzinga
  32. Medivation to Expand Global Oncology Franchise With the Acquisition ...

    Benzinga
  33. BioMarin Receives Rare Pediatric Disease Designation From FDA ...

    Benzinga
  34. BioMarin Gets Price Target Hike On Pipeline Strength

    IBD
  35. 2 DMD drugs make progress

    IBD
  36. BioMarin, Sarepta Muscular Dystrophy Drugs Progress

    IBD
  37. Baird Downgrades BioMarin Pharmaceutical To Neutral

    Benzinga
  38. Benzinga's Volume Movers

    Benzinga
  39. Benzinga's Top Downgrades

    Benzinga
  40. Mid-Afternoon Market Update: BioMarin Pharmaceutical Jumps Following ...

    Benzinga
  41. Mid-Day Market Update: Oracle Drops On Downbeat Results; Radius ...

    Benzinga
  42. BioMarin Stock Hits High On Dwarfism Drug Success

    IBD
  43. Mid-Morning Market Update: Markets Open Higher; Kroger Earnings ...

    Benzinga
  44. Benzinga's Volume Movers

    Benzinga
  45. Morning Market Gainers

    Benzinga
  46. Dollar, Data Boost Stock Futures; Oracle Tumbles, Taser Gains

    IBD
  47. Benzinga's Top #PreMarket Gainers

    Benzinga
  48. BIOMARIN PHARMA

    IBD
  49. Pier 1, BioMarin, HomeAway & Oracle Lead Wednesday's After-Hours ...

    Benzinga
  50. BMN 111 (vosoritide) Improves Growth Velocity in Children With ...

    Benzinga
  51. BioMarin Submits Drisapersen MAA to EMA for the Treatment of ...

    Benzinga
  52. Benzinga's Top Initiations

    Benzinga
  53. Barclays Initiates BioMarin Pharmaceutical With Overweight

    Benzinga
  54. Sarepta Soars On New Hope For Muscular-Dystrophy Drug

    IBD
  55. Alexion's $8.4 Billion Synageva Buyout Spooks Street

    IBD
  56. BIOMARIN PHARMA

    IBD
  57. BioMarin Completes Rolling NDA Submission to FDA for Drisapersen ...

    Benzinga
  58. J.P. Morgan's 3 Biotechnology Picks

    GuruFocus
  59. What Evercore Is Watching At BioMarin Pharmaceutical

    Benzinga
  60. BioMarin To Report Revenue In-line With Consensus, Wedbush Says

    Benzinga
  61. Why Muscular Dystrophy Is Biotech's Favorite Orphan

    IBD
  62. Bank Of America Upgrades Sarepta Therapeutics On 'Increased Conviction' ...

    Benzinga
  63. Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea

    IBD
  64. BIOMARIN PHARMA

    IBD
  65. State Of The Union Lights Up Biotech

    Benzinga
  66. Nomura Analyst Sees Fast Growth At BioMarin Pharmaceutical

    Benzinga
  67. UPDATE: Nomura Raises Price Target On BioMarin Pharmaceutical ...

    Benzinga
  68. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  69. Regeneron Jumps On Favorable Cholesterol Drug Report

    IBD
  70. 5 Potential Blockbuster Drugs Set To Launch In 2015

    IBD
  71. What Investors Are Looking For In NPS Pharmaceuticals Ahead Of ...

    Benzinga
  72. BioMarin CEO Sees Big Future For Prosensa Drug

    IBD
  73. UPDATE: UBS Securities Reiterates On BioMarin Pharmaceutical ...

    Benzinga
  74. FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion ...

    Benzinga
  75. BioMarin Will Report Breadth of Innovative Development Pipeline ...

    Benzinga
  76. Benzinga's M&A Chatter for Monday November 24, 2014

    Benzinga
  77. BioMarin buying Prosensa

    IBD
  78. Trio Of Major Deals Disclosed

    IBD
  79. Mid-Afternoon Market Update: Trina Solar Drops After Quarterly ...

    Benzinga
  80. Mid-Day Market Update: Dow Edges Lower; Platinum Underwriters ...

    Benzinga
  81. Mid-Morning Market Update: Markets Open Higher; BioMarin To Acquire ...

    Benzinga
  82. Benzinga's Volume Movers

    Benzinga
  83. BioMarin Buying Prosensa, Backing Up Troubled Drug

    IBD
  84. Stocks Hitting 52-Week Highs

    Benzinga
  85. Morning Market Movers

    Benzinga
  86. Stock Futures Trending Higher; Kate Spade Bags An Upgrade

    IBD
  87. BioMarin Pharmaceuticals To Acquire Prosensa

    Benzinga
  88. Benzinga's Top #PreMarket Gainers

    Benzinga
  89. US Stock Futures Up Ahead Of Economic Data

    Benzinga
  90. Stocks Hitting 52-Week Highs

    Benzinga
  91. Benzinga's Top Upgrades

    Benzinga
  92. Benzinga's M&A Chatter for Tuesday October 21, 2014

    Benzinga
  93. BioMarin Weathers The Storm

    Benzinga
  94. 4 Top-Rated Drugmakers Beat Q2 Earnings Estimates

    IBD
  95. Biogen Hemophilia Drugs Launch Into The Unknown

    IBD
  96. UPDATE: Credit Suisse Upgrades BioMarin Pharmaceutical

    Benzinga
  97. Benzinga's Top Upgrades

    Benzinga
  98. BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, ...

    Benzinga
  99. Amgen, BioMarin Lead Biotech Short Interest Trend (AMGN, BIIB, ...

    Benzinga
  100. Top Trending Tickers On StockTwits For February 18

    Benzinga
Trading Center